Elixir Medical has revealed details of its programme and activities during the 2017 meeting of the transcatheter cardiovascular therapeutics (TCT; 29 October–2 November, Denver, USA). It reports that as part of these activities, it will unveil “a game-changing metallic drug eluting stent platform”.
A press release for that concept, design, data from preclinical testing, and clinical programme for Elixir Medical’s DynamXTM stent will be presented, for the first time, at a signature evening symposium on 30 October (6–8pm). It adds that DynamX is a 71microns thin metallic drug-eluting stent designed to match the ease of use and acute performance of state-of-the-art drug-eluting stent. Unlike existing drug-eluting stents, however, DynamX is designed to allow the vessel to exhibit its normal pulsatile motion and adaptive remodelling capabilities.
Motasim Sirhan, founder, and CEO of Elixir Medical, says: “DynamX ushers a new era of transformation from the current metallic stents which cage the vessel into stents that allow pulsatile motion and adaptive remodelling, mimicking the normal vessel function of patients. Elixir continues its commitment to developing breakthrough adaptive remodelling technologies to better address patient needs around the world beyond the capabilities of today’s technologies.”
Also, Elixir will outline its fully bioresorbable scaffold programs and will present its latest trial results throughout TCT.
11am: Mile High Ballroom 2A-3A, Ballroom Level
Drug eluting scaffold with an absorbable platform for primary lower extremity arterial revascularization: Desappear study initial results with prava
6–8pm: Hyatt Regency Centennial Ballroom D-E
ELIXIR SYMPOSIUM: DynamX TM Redefining Interventional Cardiology
9.45am: Moderated Posters 4, Exhibit Hall, Exhibit Level
Multicentre evaluation of a novel 120µm novolimus-eluting, fully bioresorbable coronary scaffold:
10.06am: Moderated Posters 4, Exhibit Hall, Exhibit Level
Multicentre post-marketing evaluation of the Elixir Desolve novolimus eluting bioresorbable coronary stent system: 24-month results from the Desolve PMCF study
12.06pm: Moderated Posters 3, Exhibit Hall, Exhibit Level
Drug eluting scaffold with an absorbable platform for primary lower extremity arterial revascularization – Desappear study initial results
1.45pm: Room 709/711, Meeting Room Level
Prospective, multicentre evaluation of the Desolve novolimus-eluting bioresorbable coronary scaffold – imaging outcomes and five-year clinical and imaging results
3.21pm: Room 210, Meeting Room Level, Virtual Didactic
The Desyne novolimus-eluting coronary stent: results from the Excella trials
4.33pm: Mile High Ballroom 4E-4F, Ballroom Level
Desolve Nx, Cx, and amity: a family of progressively thinner-Strut PLLA-Based BRS with novel properties
7.05pm: Hyatt Regency Denver at Colorado Convention Center Continental Ballroom F-H
A “novel” metallic DES with bioresorbable polymer- The Elixir DynamX Program
7.40pm: Hyatt Regency Denver at Colorado Convention Center Continental Ballroom F-H
The BRS Landscape: Where do we Stand? (ABSORB, MAGNITUDE, DESolve, FANTOM, and DREAMS-2G)